Product Images Docetaxel

DFS Probability refers to the probability of survival without disease progression after a certain period of time. The chart shows a K-M Curve Plot for Disease Free Survival (DFS) with time (in months) along the X-axis and DFS probability (%) plotted on the Y-axis. The graph provides information about the DFS probability of a group of patients over a period of time. The table at the bottom of the chart indicates the time intervals in months. However, the last line is not clear and appears to have errors, resulting in the text "Dicunn SinuAomsival P timorting". Hence, the information about the last line is unavailable.*

The given text seems to be a part of a graph or a chart showing the "Overall Survival K-M Curve" of "TAX316". The X-axis represents "Survival Time (months)" whereas the Y-axis has no label but shows the percentage of survival rates ranging from 0 to 80%. *

This is a medical figure showing the survival K-M curves of patients treated with Docetaxel 75 mg/m? compared to Best Supportive Care. The x-axis represents survival time in months, and the y-axis represents the probability of survival. The graph shows that the group treated with Docetaxel had a higher overall survival rate compared to Best Supportive Care, with a p-value of 0.010.*

The text describes a figure labeled "Figure 4 - TAX320 Survival K-M Curves" which compares the overall survival rate of Docetaxel 75mg/m² with Vinorelbine or Ifosfamide Control using K-M curves. The x-axis represents the survival time in months while the y-axis represents the survival probability. A logarithmic rank test was performed with a p-value of 0.18. The figure includes a legend and it shows survival probabilities at different time points.*

The text represents a graph titled "TAX327 Survival K-M Curves" that shows the survival probability over time (measured in months) on the x-axis, ranging from 0 to 30. The y-axis ranges from 0.3 to 1 and represents the survival probability. The graph includes four lines of different colors representing different survival probabilities for the study or treatment being measured. No further information is available.*

The text describes a figure labeled "Figure 6 - Gastric Cancer Study (TAX325) Time to Progression K-M Curve". The figure displays a graph with a y-axis labeled "Probability (%)" and an x-axis labeled "Time (months)". The graph shows a curved line indicating the probability of time to progression in gastric cancer patients. The probability starts at 100% and decreases over time. However, some text is missing from the graph, as there is a missing line between 70 and 50 in the probability axis.*

This is a figure from the Gastric Cancer Study (TAX325), showing the Survival K-M Curve. It includes a chart with 1009 individuals and measures the Survival Probability in percentages over a period of 36 months.*

The text is a graph displaying the progression-free survival rate of TAX323. The X-axis represents the progression-free survival time in months while the Y-axis represents the percentage probability of PFS. The graph shows that after 6 months, the probability of PFS decreased from 100% to 90%. After 18 months of PFS among the patients taking TAX323, only 50% maintained the progression-free survival.*

The text is a figure caption presenting the survival probability in percentage and the survival time in months using a K-M curve for TAX323 Overall Survival. It includes a graph with survival probability values from 0 to 100 at different time intervals between 24 to 48 months.*

Figure 10 shows the overall survival probability of patients with TPF (n=255) and PF (n=246) treatments measured over a period of 72 months. The survival probability of the former is higher than the latter at all time points. The number of patients at risk for each group is also shown.*

This is a prescription drug with NDC code 0409-4235-01, which is called Docetaxel Injection, USP. It has a concentration of 20 mg/mL and is intended for intravenous use only. It comes in a single-dose vial and should be stored between 2°C and GULORUGS/BZNZT. The last line appears to be a reference code or number.*

This text seems to be a label for a medication called Docetaxel, with a concentration of 80mg/4mL. It is ready to be added for intravenous use and should be used within 28 days of storage. The label advises to check concentration before preparation and refers to the package insert for complete instructions.*

This is a description of a sterile multipledose vial of Docetaxel Injection, USP containing 160 Mg/8 ML of the drug. The NDC number of the vial is 0409-0365-01 and it has a strength of 20 mg/mL. The text is not clear on some parts of the text and contains some errors.*